Pharmacology News and Research

Latest Pharmacology News and Research

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the fourth quarter and full-year ended December 31, 2010, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL and established 2011 financial guidance.

31 Mar 2011

Foundation for nationwide consensus on access to genetic information

Health privacy is a serious concern, but as genetic testing becomes more common, access to your genetic information raises questions the healthcare industry has never faced before. It is particularly important that we begin to address these questions now that genomic information is being collected to improve the diagnosis and treatment of children.

31 Mar 2011

Study provides insight into kidney cancer

Researchers at UT Southwestern Medical Center have discovered genetic pathways to starve selectively kidney cancer cells.

31 Mar 2011

Gilead and Yale enter multi-year cancer research collaboration

Gilead Sciences, Inc. and Yale School of Medicine today announced the formation of a multi-year research collaboration focused on the discovery of novel cancer therapies. The research effort will initially span four years with an option to renew for up to ten years.

30 Mar 2011

Natural disasters can produce major lung problems

A comprehensive new review published in the journal Respirology indicates that lung problems are major causes of morbidity and mortality following natural disasters.

29 Mar 2011

CINJ scientist receives University of Texas award for cancer therapeutic research

In recognition of efforts made in cancer therapeutic research, Joseph R. Bertino, MD, chief scientific officer at The Cancer Institute of New Jersey, has been honored with The Jeffrey A. Gottlieb Memorial Award sponsored by The University of Texas MD Anderson Cancer Center. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

29 Mar 2011

SpHb sensor can monitor blood hemoglobin levels during spine surgery

A spectrophotometric hemoglobin sensor may become a useful new approach to noninvasive monitoring of blood hemoglobin levels during surgery, reports a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Mar 2011

CPRIT awards $36.7 million grant to UT Southwestern for cancer research

The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.

29 Mar 2011

Challenges of high-risk surgery

A small group of "high-risk" patients account for a disproportionately high number of surgery-related deaths, complications, and costs. The April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS), commences a special series on high-risk surgery—focusing on new and emerging strategies for identifying and managing patients at high risk.

28 Mar 2011

A.P. Pharma fourth quarter revenue decreases to $1.6 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2010 and provided a corporate update.

28 Mar 2011

University of Aberdeen, TPP enter agreement to develop novel future medicines

TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.

28 Mar 2011

Molecular pharmacologist receives AACR Award for cancer research

Susan Band Horwitz, Ph.D., will receive the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel, which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas.

28 Mar 2011

Zileuton can help reduce amyloid plaque formation and Alzheimer's development

A drug used to treat asthma has been shown to help reduce the formation of amyloid beta, a peptide in the brain that is implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine.

28 Mar 2011

Study identifies unique adult animal stem cells that can turn into neurons

A group of scientists at Marshall University is conducting research that may someday lead to new treatments for repair of the central nervous system.

25 Mar 2011

Study develops new approaches for sorting out complexities of cancer cells

New drugs that specifically target the mutated genes responsible for cancer growth have shown great success in extending the lives of patients, with far fewer side effects than conventional anti-cancer therapies. Unfortunately, many patients become resistant to these drugs due to secondary mutations.

25 Mar 2011

AssureRx closes $11 million Series B financing

AssureRx Health, Inc. today announced the closing of an $11 million Series B financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug and the right dose for individual neuropsychiatric patients, will use the funds to expand direct sales and marketing for its first product, GeneSightRx®, and for second generation product development activities.

25 Mar 2011

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.

25 Mar 2011

Scientists discover hormone pathway that can lead to new diabetes treatment

Researchers at UT Southwestern Medical Center have discovered a hormone pathway that potentially could lead to new ways of treating type 1 diabetes independent of insulin, long thought to be the sole regulator of carbohydrates in the liver.

25 Mar 2011

Perceptive Informatics announces eClinical Product Suite survey results

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced results of a survey conducted during its recent webinar entitled "Designing and Delivering an eClinical Product Suite."

From Parexel 24 Mar 2011